FILE – This Wednesday, Sept, 2, 2020, file photo shows University of Miami Miller School of Medicine lab tech Sendy Puerto processing blood samples in the specimen processing lab from study participants who volunteered to take part in testing the National Institutes of Health-funded Moderna COVID-19 vaccine in Miami. (AP Photo/Taimy Alvarez, File)
OAN Newsroom
UPDATED 7:57 AM PT – Friday, November 20, 2020
The CEO of biotechnology company Moderna has continued to highlight progress in the fight against the novel coronavirus.
While speaking virtually at the Bloomberg New Economy Forum on Thursday, Stephane Bancel reiterated their vaccine is more than 95 percent effective. He believes the promising results from late stage studies offers hope that they are on the right path.
Bancel went on to call it “a game changer.” His comments come as the Trump administration continues to work with the company to speed up production and distribution of a vaccine to the American people as soon as possible.
We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.
Read more: https://t.co/vYWEy8CKCv pic.twitter.com/YuLubU1tlx— Moderna (@moderna_tx) November 16, 2020
“But what I think we can do for next time is be able to go much faster…a couple of moves to approval of a vaccine, I think it is doable,” Bancel stated. “We already have investment up front and then investing in manufacturing because to stop those type of viruses, you need a very, very high vaccination rate.”
The CEO went on to say Moderna will have 20 million doses of the vaccine by the end of the year ready to ship as soon as they get regulatory approval.
RELATED: Pfizer, BioNTech, Moderna to apply for emergency use authorization for COVID-19 vaccine
Be the first to comment